Anixa Biosciences (ANIX) Interest & Investment Income (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Interest & Investment Income came in at $111000.0 in Q2 2026, down 41.58% YoY from $190000.0 in Q2 2025, and down 27.92% on a QoQ basis from $154000.0 in Q4 2025.
Anixa Biosciences (ANIX) Interest & Investment Income (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Interest & Investment Income data on file, last reported at $111000.0 in Q2 2026.
- Quarterly Interest & Investment Income fell 41.58% year-over-year to $111000.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $611000.0 (down 31.35% YoY) and the FY2025 annual result came in at $673000.0, down 40.6% from the prior year.
- Interest & Investment Income slipped to $111000.0 in Q2 2026, from $154000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $330000.0 in Q4 2023 to a low of $1000.0 in Q1 2022.
- A 5-year average of $182470.6 and a median of $190000.0 in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2023 — Interest & Investment Income surged 25200.0% — and 2025, when it slumped 45.77%.
- Tracing ANIX's Interest & Investment Income over 5 years: stood at $80000.0 in 2022, then soared by 312.5% to $330000.0 in 2023, then decreased by 24.24% to $250000.0 in 2024, then plunged by 38.4% to $154000.0 in 2025, then slipped by 27.92% to $111000.0 in 2026.
- The last three Interest & Investment Income figures came in at $111000.0 (Q2 2026), $154000.0 (Q4 2025), and $156000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | 111,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 111,000.00 |
| Oct 31, 2025 | 154,000.00 |
| Jul 31, 2025 | 156,000.00 |
| Apr 30, 2025 | 190,000.00 |
| Jan 31, 2025 | 173,000.00 |
| Oct 31, 2024 | 250,000.00 |
| Jul 31, 2024 | 277,000.00 |
| Apr 30, 2024 | 287,000.00 |
| Jan 31, 2024 | 319,000.00 |
| Oct 31, 2023 | 330,000.00 |
| Jul 31, 2023 | 296,000.00 |
| Apr 30, 2023 | 253,000.00 |
| Jan 31, 2023 | 202,000.00 |
| Oct 31, 2022 | 80,000.00 |
| Jul 31, 2022 | 22,000.00 |
| Apr 30, 2022 | 1,000.00 |
| Jan 31, 2022 | 1,000.00 |
| Jul 31, 2021 | 626.00 |
| Apr 30, 2021 | 393.00 |
| Jan 31, 2021 | 1,000.00 |